Trials / Conditions / Refractory Hematologic Malignancy

Refractory Hematologic Malignancy

7 registered clinical trials studyying Refractory Hematologic Malignancy — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products NCT05713214	St. Jude Children's Research Hospital	—
Recruiting	International Leukemia Target Board NCT05270096	Princess Maxima Center for Pediatric Oncology	—
Withdrawn	A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. NCT05205252	Epizyme, Inc.	Phase 1 / Phase 2
Completed	Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies NCT04681105	City of Hope Medical Center	Phase 1
Withdrawn	Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer NCT03739606	City of Hope Medical Center	Phase 2
Terminated	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524	OHSU Knight Cancer Institute	Phase 1
Recruiting	CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractor NCT03328078	Curis, Inc.	Phase 1 / Phase 2